APOE ε4 polymorphism has been recently described as a possible association with cognitive deficits in COVID-19 patients. This research aimed to establish the correlation between COVID-19 and cognitive impairment, and the APOE gene polymorphism among outpatients. We performed a cross-sectional study with confirmed COVID-19 patients and neurological symptoms that persisted for more than three months from onset. APOE genotypes were determined. The final number of patients included in this study was 219, of which 186 blood samples were collected for APOE genotyping, evaluated 4.5 months after COVID-19. Among the participants, 143 patients (65.3%) reported memory impairment symptoms as their primary concern. However, this complaint was objectively verified through screening tests (Addenbrooke Cognitive Examination-Revised and Mini-Mental State Examination) in only 36 patients (16.4%). The group experiencing cognitive decline exhibited a higher prevalence of the APOE ε4 allele than the normal group (30.8% vs. 16.4%, respectively, p = 0.038). Furthermore, the APOE ε4 allele and anxiety symptoms remained significant after multivariate analysis. This study assessed an outpatient population where cognitive changes were the primary complaint, even in mild cases. Moreover, the ε4 allele, sleep disorders, and anxiety symptoms were more frequent in the cognitive decline group.
Background Olfactory dysfunction (OD) represents a frequent manifestation of the coronavirus disease 2019 (COVID-19). Apolipoprotein E (APOE) is a protein that interacts with the angiotensin-converting enzyme receptor, essential for viral entry into the cell. Previous publications have suggested a possible role of APOE in COVID-19 severity. As far as we know, no publications found significant associations between this disease's severity, OD, and APOE polymorphisms (E2, E3, and E4). Objective To analyze the epidemiology of OD and its relationship with APOE polymorphisms in a cohort of Long-COVID patients. Methods We conducted a prospective cohort study with patients followed in a post-COVID neurological outpatient clinic, with OD being defined as a subjective reduction of olfactory function after infection, and persistent OD being defined when the complaint lasted more than 3 months after the COVID-19 infection resolution. This cross-sectional study is part of a large research with previously reported data focusing on the cognitive performance of our sample. Results The final sample comprised 221 patients, among whom 186 collected blood samples for APOE genotyping. The persistent OD group was younger and had a lower hospitalization rate during the acute phase of the disease (p < 0.001). Furthermore, the APOE variant E4 allele frequency was lower in this group (p = 0.035). This study evaluated OD in an outpatient population with COVID-19. In the current literature on this disease, anosmia is associated with better clinical outcomes and the E4 allele is associated with worse outcomes. Conclusion Our study provides new information to these correlations, suggesting APOE E4 as a protective factor for OD.
This paper presents an analysis of the influence of the switched reluctance machine design parameters on its steady-state operation characteristics (phase inductance, phase current and mechanical output torque). The present analysis is carried out using computational simulation, based on the constructive parameters of a SRM designed by the authors. It is also suggested applications for incoming studies.
Background: COVID‐19 neurological manifestations were demonstrated during the pandemic, including cognitive impairment. Objectives: To determine the prevalence of cognitive and behavioral complaints (such as dementia, MCI or SCD) in a outpatient sample with recent SARS‐COV2 infection. Specific: Evaluate the association of cognitive impairment with the presence of the polymorphism found in the APOE gene and with respiratory diseaseMethod: Observational, longitudinal, prospective clinical study. Inclusion criteria: patients with confirmed Covid‐19. Patients are evaluated in an outpatient clinic. They are evaluated through a standardized attendance record, with somatic and cognitive neurological assessment. Cognitive assessment involves the application of cognitive (ACER, MMSE and CDR), functional (Pfeffer) and psychiatric (GDS or Beck) screening instruments, in addition to subsequent extensive neuropsychological assessment. In addition, APOE polymorphism is analysed.Results: To date, 200 patients were evaluated. The average age is 46.5 years, with 65.4% female, 79.16% with 8 or more years of schooling, in addition to 57.5% of the sample with cognitive complaints.Conclusions: The results so far in our study demonstrate that cognitive complaints are frequent in patients even in the chronic phase of the disease.
Post coronavirus disease (COVID) syndrome is a frequent condition, resulting from the persistence of symptoms or the development of new ones, after 12 weeks of acute severe acute respiratory syndrome coronavirus 2 infection. The impact on sleep was observed worldwide, whether in the acute phase due to the direct effect of the infection or due to changes in patients' circadian cycle imposed by new routines during quarantine, dysfunctional habits, and social isolation. Given the persistence of sleep-related symptoms in patients with long-term COVID syndrome, we decided to follow-up and reassess these patients after 1 year. The present is an observational, longitudinal, and prospective clinical study. The study took place in two stages: the first assessment between October 2020 and September 2021, with reassessment after 1 year. Participants underwent the application of the Geriatric Depression Scale (GDS) or the Beck Inventory, Addenbrooke's Cognitive Examination - Revised (ACE-R) and Mini-Mental State Examination (MMSE). The evaluation of sleep disorders involved a comprehensive clinical history obtained through a structured questionnaire. Of the 46 cases with sleep complaints, 7 refused to return for a new assessment. Thus, 39 patients were included, of which 9 persisted with insomnia (23.07%) and 2 patients persisted with central hypersomnia (5.12%). The persistence of cognitive complaints was also higher in patients with insomnia when compared with those without it (N = 5; 56%, p = 0.001). Given the persistence of patients with insomnia and central hypersomnia, the damage to the central nervous system may be lasting, reinforcing the need for follow-up.